320 related articles for article (PubMed ID: 34345815)
1. Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review.
Kifle ZD
Metabol Open; 2021 Sep; 11():100116. PubMed ID: 34345815
[TBL] [Abstract][Full Text] [Related]
2. The Possible Role of Bruton Tyrosine Kinase Inhibitors in the Treatment of COVID-19: A Review.
Rezaei M; Barati S; Babamahmoodi A; Dastan F; Marjani M
Curr Ther Res Clin Exp; 2022; 96():100658. PubMed ID: 34931090
[TBL] [Abstract][Full Text] [Related]
3. BTK inhibitors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A systematic review.
Stack M; Sacco K; Castagnoli R; Livinski AA; Notarangelo LD; Lionakis MS
Clin Immunol; 2021 Sep; 230():108816. PubMed ID: 34352390
[TBL] [Abstract][Full Text] [Related]
4. Observations on the use of Bruton's tyrosine kinase inhibitors in SAR-CoV-2 and cancer.
Benner B; Carson WE
J Hematol Oncol; 2021 Jan; 14(1):15. PubMed ID: 33441177
[TBL] [Abstract][Full Text] [Related]
5. Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features.
Shirley M
Target Oncol; 2022 Jan; 17(1):69-84. PubMed ID: 34905129
[TBL] [Abstract][Full Text] [Related]
6. BTK inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Systematic Review.
Stack M; Sacco K; Castagnoli R; Livinski AA; Notarangelo LD; Lionakis MS
Res Sq; 2021 Mar; ():. PubMed ID: 33791689
[TBL] [Abstract][Full Text] [Related]
7. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
Shadman M; Flinn IW; Levy MY; Porter RF; Burke JM; Zafar SF; Misleh J; Kingsley EC; Yimer HA; Freeman B; Rao SS; Chaudhry A; Tumula PK; Gandhi MD; Manda S; Chen DY; By K; Xu L; Liu Y; Crescenzo R; Idoine A; Zhang X; Cohen A; Huang J; Sharman JP
Lancet Haematol; 2023 Jan; 10(1):e35-e45. PubMed ID: 36400069
[TBL] [Abstract][Full Text] [Related]
8. Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile.
Barf T; Covey T; Izumi R; van de Kar B; Gulrajani M; van Lith B; van Hoek M; de Zwart E; Mittag D; Demont D; Verkaik S; Krantz F; Pearson PG; Ulrich R; Kaptein A
J Pharmacol Exp Ther; 2017 Nov; 363(2):240-252. PubMed ID: 28882879
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI.
Nicolson PLR; Hughes CE; Watson S; Nock SH; Hardy AT; Watson CN; Montague SJ; Clifford H; Huissoon AP; Malcor JD; Thomas MR; Pollitt AY; Tomlinson MG; Pratt G; Watson SP
Haematologica; 2018 Dec; 103(12):2097-2108. PubMed ID: 30026342
[TBL] [Abstract][Full Text] [Related]
10. Relevance of the Bruton Tyrosine Kinase as a Target for COVID-19 Therapy.
Rada M; Qusairy Z; Massip-Salcedo M; Macip S
Mol Cancer Res; 2021 Apr; 19(4):549-554. PubMed ID: 33328281
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.
Patel V; Balakrishnan K; Bibikova E; Ayres M; Keating MJ; Wierda WG; Gandhi V
Clin Cancer Res; 2017 Jul; 23(14):3734-3743. PubMed ID: 28034907
[No Abstract] [Full Text] [Related]
12. Zanubrutinib in lymphoproliferative disorders: a comprehensive review.
Muñoz J; Wang Y; Jain P; Wang M
Ther Adv Hematol; 2022; 13():20406207221093980. PubMed ID: 35651781
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.
Roschewski M; Lionakis MS; Sharman JP; Roswarski J; Goy A; Monticelli MA; Roshon M; Wrzesinski SH; Desai JV; Zarakas MA; Collen J; Rose K; Hamdy A; Izumi R; Wright GW; Chung KK; Baselga J; Staudt LM; Wilson WH
Sci Immunol; 2020 Jun; 5(48):. PubMed ID: 32503877
[TBL] [Abstract][Full Text] [Related]
14. The Evolution of Therapies Targeting Bruton Tyrosine Kinase for the Treatment of Chronic Lymphocytic Leukaemia: Future Perspectives.
Eyre TA; Riches JC
Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174062
[TBL] [Abstract][Full Text] [Related]
15. Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice.
O'Riordan CE; Purvis GSD; Collotta D; Chiazza F; Wissuwa B; Al Zoubi S; Stiehler L; Martin L; Coldewey SM; Collino M; Thiemermann C
Front Immunol; 2019; 10():2129. PubMed ID: 31552054
[TBL] [Abstract][Full Text] [Related]
16. Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
Joseph RE; Amatya N; Fulton DB; Engen JR; Wales TE; Andreotti A
Elife; 2020 Nov; 9():. PubMed ID: 33226337
[TBL] [Abstract][Full Text] [Related]
17. Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.
Wolska-Washer A; Robak T
Expert Rev Hematol; 2022 Mar; 15(3):183-194. PubMed ID: 35296194
[TBL] [Abstract][Full Text] [Related]
18. Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies.
Song Y; Wu SJ; Shen Z; Zhao D; Chan TSY; Huang H; Qiu L; Li J; Tan TD; Zhu J; Song Y; Huang WH; Zhao W; Liu HSY; Xu W; Chen N; Ma J; Chang CS; Tse EWC
Exp Hematol Oncol; 2023 Oct; 12(1):92. PubMed ID: 37845755
[TBL] [Abstract][Full Text] [Related]
19. Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19.
Kaliamurthi S; Selvaraj G; Selvaraj C; Singh SK; Wei DQ; Peslherbe GH
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34209188
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib and Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Focus on Atrial Fibrillation and Ventricular Tachyarrhythmias/Sudden Cardiac Death.
Boriani G; Menna P; Morgagni R; Minotti G; Vitolo M
Chemotherapy; 2023; 68(2):61-72. PubMed ID: 36366814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
